CA2773478C - System for determining unprocessed and partially processed neurotoxin type a - Google Patents

System for determining unprocessed and partially processed neurotoxin type a Download PDF

Info

Publication number
CA2773478C
CA2773478C CA2773478A CA2773478A CA2773478C CA 2773478 C CA2773478 C CA 2773478C CA 2773478 A CA2773478 A CA 2773478A CA 2773478 A CA2773478 A CA 2773478A CA 2773478 C CA2773478 C CA 2773478C
Authority
CA
Canada
Prior art keywords
bont
unprocessed
partially processed
polypeptides
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2773478A
Other languages
English (en)
French (fr)
Other versions
CA2773478A1 (en
Inventor
Harold V. Taylor
Karl-Heinz Eisele
Cornelia Bruenn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Pharma GmbH and Co KGaA
Original Assignee
Merz Pharma GmbH and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41466928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2773478(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma GmbH and Co KGaA filed Critical Merz Pharma GmbH and Co KGaA
Publication of CA2773478A1 publication Critical patent/CA2773478A1/en
Application granted granted Critical
Publication of CA2773478C publication Critical patent/CA2773478C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96419—Metalloendopeptidases (3.4.24)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
CA2773478A 2009-10-21 2010-10-18 System for determining unprocessed and partially processed neurotoxin type a Active CA2773478C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27945309P 2009-10-21 2009-10-21
EP09173612 2009-10-21
EP09173612.4 2009-10-21
US61/279,453 2009-10-21
PCT/EP2010/065618 WO2011048044A1 (en) 2009-10-21 2010-10-18 System for determining unprocessed and partially processed neurotoxin type a

Publications (2)

Publication Number Publication Date
CA2773478A1 CA2773478A1 (en) 2011-04-28
CA2773478C true CA2773478C (en) 2018-07-17

Family

ID=41466928

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2773478A Active CA2773478C (en) 2009-10-21 2010-10-18 System for determining unprocessed and partially processed neurotoxin type a

Country Status (15)

Country Link
US (2) US8841080B2 (enExample)
EP (1) EP2491384B1 (enExample)
JP (1) JP5709877B2 (enExample)
KR (1) KR101788340B1 (enExample)
CN (1) CN102597769B (enExample)
AU (1) AU2010309932B2 (enExample)
BR (1) BR112012009436A2 (enExample)
CA (1) CA2773478C (enExample)
ES (1) ES2449303T3 (enExample)
IL (1) IL218455A (enExample)
IN (1) IN2012DN01954A (enExample)
MX (1) MX2012004454A (enExample)
PT (1) PT2491384E (enExample)
RU (1) RU2545825C9 (enExample)
WO (1) WO2011048044A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1786459B1 (en) * 2004-07-26 2014-02-12 Merz Pharma GmbH & Co. KGaA Therapeutic composition whit a botulinum neurotoxin
RU2549463C1 (ru) * 2013-12-03 2015-04-27 Федеральное бюджетное учреждение науки Государственный научный центр прикладной микробиологии и биотехнологии (ФБУН ГНЦ ПМБ) Способ определения ботулинического нейротоксина типа а на основе иммунодетекции, сопряженной с полимеразной цепной реакцией
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067700A2 (en) 1999-05-12 2000-11-16 United States Army Medical Research & Materiel Cmd Recombinant vaccine against botulinum neurotoxin
WO1999037326A1 (en) * 1998-01-26 1999-07-29 University Of Massachusetts Biologically active hemagglutinin from type a clostridium botulinum and methods of use
US6667158B1 (en) * 1998-12-17 2003-12-23 The United States Of America As Represented By The Secretary Of The Army Antibodies against type a botulinum neurotoxin
US20080171347A1 (en) * 2003-04-11 2008-07-17 Atassi M Zouhair Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides
FR2869908B1 (fr) * 2004-05-05 2006-07-28 Pharmaleads Substrat peptidique reconnu par la toxine botulique de type a, bont/a et son utilisation pour detecter et/ou doser ladite toxine ou des inhibiteurs de son activite
CN100575363C (zh) * 2007-03-07 2009-12-30 中国人民解放军军事医学科学院微生物流行病研究所 人源抗a型肉毒神经毒素基因工程抗体及其制备方法与用途
US7732579B2 (en) * 2007-06-13 2010-06-08 The United States Of America As Represented By The Secretary Of Agriculture High-affinity monoclonal antibodies for botulinum toxin type A
BRPI1008885B1 (pt) * 2009-02-19 2021-09-28 Merz Pharma Gmbh & Co. Kgaa Método para obter uma solução purificada de polipeptídeos de neurotoxina processados e composição
CN101503472B (zh) * 2009-03-17 2011-08-10 中国人民解放军军事医学科学院生物工程研究所 抗a型肉毒毒素的人源性中和抗体及其应用

Also Published As

Publication number Publication date
KR101788340B1 (ko) 2017-10-19
CA2773478A1 (en) 2011-04-28
US9213026B2 (en) 2015-12-15
EP2491384A1 (en) 2012-08-29
RU2545825C2 (ru) 2015-04-10
EP2491384B1 (en) 2013-12-04
BR112012009436A2 (pt) 2017-02-21
IL218455A0 (en) 2012-04-30
JP2013508701A (ja) 2013-03-07
PT2491384E (pt) 2014-02-21
US20120214182A1 (en) 2012-08-23
RU2012120572A (ru) 2013-11-27
CN102597769B (zh) 2014-11-05
RU2545825C9 (ru) 2015-06-20
AU2010309932A1 (en) 2012-04-05
MX2012004454A (es) 2012-05-22
AU2010309932B2 (en) 2015-04-16
US20140349322A1 (en) 2014-11-27
KR20120102639A (ko) 2012-09-18
ES2449303T3 (es) 2014-03-19
IL218455A (en) 2015-10-29
US8841080B2 (en) 2014-09-23
JP5709877B2 (ja) 2015-04-30
CN102597769A (zh) 2012-07-18
HK1173493A1 (zh) 2013-05-16
WO2011048044A1 (en) 2011-04-28
IN2012DN01954A (enExample) 2015-08-21

Similar Documents

Publication Publication Date Title
AU2010214834B2 (en) Means and methods for manufacturing highly pure neurotoxin
AU2010243692B2 (en) Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities
US20060177881A1 (en) Antibodies against type A botulinum neurotoxin
US9213026B2 (en) System for determining unprocessed and partially processed neurotoxin type A
HK1173493B (en) System for determining unprocessed and partially processed neurotoxin a polypeptide
HK1169171B (en) Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities
HK1165436A (en) Means and methods for manufacturing highly pure neurotoxin
HK1165436B (en) Means and methods for manufacturing highly pure neurotoxin

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150804

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251020

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251208

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260203